INBX · Inhibrx Biosciences, Inc.
$94.56
-2.43 (-2.51%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$1.47B
Shares
14.72M
Volume · Oct 5
207.09K
Avg daily vol (3M)
304.41K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$94.56
Open$97.56
Day$94.18–98.51
52W close$28.36–141.84
Avg vol 30d339K
Short int3.4M · 23.1% float · 8.3d
Short vol40%
Last earningsSep 8, 2026
DataMay 2024–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Jan 6, 2027
Est · unconfirmed
· in 13 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$138.18M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-10,386.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$42.94M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.3%
Year over year · more shares
Price change (1Y)
+176.6%
Trailing year
Short interest
23.1%
Latest settlement · 8.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−8%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
58%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
+14%
trailing
YTD return
+20%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $102 › 200d $91 — 50d above 200d
Institutional flow
Distributing
2 of 166 funds reported for Sep 30 · net -5 sh shares
Insider flow
Accumulating
Net +$5.2M over 90 days · 25% sells
Short interest
Rising
23.06% of float · ▲ +2.9% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
166 holders — near 2-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+550%
Y/Y
EPS growth
−108%
Y/Y
Free cash flow
$-129.8M
Quant / Vol
risk profile
Volatility
130%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
58%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $102 › 200d $91 — 50d above 200d
Institutional flow
Distributing
2 of 166 funds reported for Sep 30 · net -5 sh shares
Insider flow
Accumulating
Net +$5.2M over 90 days · 25% sells
Short interest
Rising
23.06% of float · ▲ +2.9% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
166 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $28
Now $95 · 58%
Range high $142
vs 200-day avg +4%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INBX
this stock
Inhibrx Biosciences, Inc.
|
$1.47B | +19.7% | +550.0% | — | 23.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INBX | -7.0% | -22.0% | +13.7% | -5.5% | +19.7% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -8.2% | -22.6% | +2.1% | -7.1% | +6.1% |